Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DPC Stock Soars 67% In 3Q On Strength Of Immulite Sales, IVD Market Growth

This article was originally published in The Gray Sheet

Executive Summary

Solid sales of Diagnostic Products Corp.' s reagents for the Immulite immunoassay platform, combined with revived growth in the immunoassay segment of the in vitro diagnostic market triggered a 67.2% gain in the company's stock price during the third quarter of 2000.
Advertisement

Related Content

Abbott's AFP, CA 125 Cancer Tests Unaffected By Consent Decree
DPC Places 10-15 Immulite 2000 Units In U.S. Since Launch In Early March
DPC Places 10-15 Immulite 2000 Units In U.S. Since Launch In Early March
Advertisement
UsernamePublicRestriction

Register

MT013987

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel